The American Journal of Managed Care3h
Breakthrough Drugs Set to Achieve Blockbuster Status by 2030
Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.
pharmaphorum12h
Pharma holds it breath for ’25 as the sun shines on JP Morgan conference
The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Medical News Today10h
Calorie restriction plus common diabetes drug leads to higher remission rates
A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
Patients with diabetes have comparable health expenses after Roux-en-Y gastric bypass or sleeve gastrectomy
For patients with diabetes undergoing Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), overall expenditures ...
FDA approves Ozempic for kidney disease treatment in diabetes patients
The U.S. Food and Drug Administration (FDA) has granted approval for an expanded use of Ozempic® (semaglutide) injection, ...